APTOF · Aptose Biosciences Inc.
$1.69
+0.00 (+0.00%)
At close · Jul 3
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“our ability to continue as a going concern; - our need to raise substantial additional capital in the near future and our ability to raise such funds when needed and on acceptable terms; - if a financing is completed, it may not be a large enough financing to fully fund the company's operations”View the 10-Q filed May 13, 2026
Market Cap
$4.31M
Shares
2.55M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2025
Net Income
-$25.47M
-0.1%
FY2025
Diluted EPS
-$10.41
+71.4%
FY2025
Operating Cash Flow
-$21.99M
+38.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | |
| $12.6M | $11.34M | $15.1M | $33.27M | $24.53M | $45.99M | $29.29M | $16.84M | $18.73M | $6.27M | |
| $13.85M | $13.38M | $11.15M | $15.59M | $14.51M | $19.46M | $26.48M | $10.02M | $10.37M | $5.55M | |
| $46K | — | — | $88K | $120K | $150K | $152K | $152K | $87K | $84K | |
| $26.44M | $24.72M | $26.26M | $52.36M | $42.6M | $65.45M | $55.77M | $26.86M | $29.11M | $11.83M | |
| — | $105K | $357K | $1.15M | $788K | $94K | $522K | $574K | $283K | $68K | |
| -$1.12M | -$745K | $827K | $1.15M | $779K | $93K | $530K | $580K | $239K | $183K | |
| — | $0 | $0 | — | — | — | — | — | — | — | |
| -$27.56M | -$25.47M | -$25.43M | -$51.21M | -$41.82M | -$65.35M | -$55.24M | -$26.28M | -$28.87M | -$11.64M | |
| -$21.12M | — | -$25.43M | -$51.21M | -$41.83M | -$65.35M | -$55.26M | -$26.26M | -$28.87M | -$11.66M | |
| USD/shares | — | -$10.41 | -$36.38 | -$227.43 | -$204.00 | -$328.50 | — | — | — | — |
| USD/shares | — | -$10.41 | -$36.38 | -$227.43 | -$204.00 | -$328.50 | — | — | — | — |
| shares | — | 2.45M | 698.98K | 225.15K | 205.03K | 197.9689 | 181.86K | 111.47K | 74.2K | 49.58K |
| shares | — | 2.45M | 698.98K | 225.15K | 205.03K | 197.9689 | 181.86K | 111.47K | 74.2K | 49.58K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.77×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 150 similar-size Biotechnology companies (of 546 listed).